New product: Xadago (safinamide) 50 and 100mg film-coated tablets -

New product: Xadago (safinamide) 50 and 100mg film-coated tablets
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Neurological disorders
Summary
Safinamide, a highly selective and reversible MAO-B inhibitor, is licensed for treatment of patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of levodopa alone or in combination with other PD drugs in mid-to late-stage fluctuating patients.
UKMi comment
The Midlands Therapeutics Review and Advisory Committee (MTRAC) has issued a series of considerations for commissioners when assessing the commissioning of safinamide.
Related links: MTRAC commissioning guidance